Introduction {#s1}
============

Ventricular infection from multidrug-resistant (MDR) *Acinetobacter baumannii* (*A. baumannii*) is one of the most severe complications of craniotomy, with a mortality rate reaching up to 71% ([@B1]), and the drugs used to treat these infections have poor CSF penetration. Intraventricular (IVT) and intravenous (IV) colistin are used as the last resort of treatment of MDR *A. baumannii* ventriculitis/meningitis. However, the colistin-associated neurotoxicity, reported in up to 21.7% of the cases ([@B2]), limits its use. Tigecycline is an antibiotic with an excellent activity against a broad spectrum of MDR pathogens, including *Acinetobacter baumannii* and *Klebsiella pneumoniae*, with a favorable toxicity profile. The use of tigecycline received approval from the Food and Drug Administration in the USA in 2005, and currently, this drug can only be administered intravenously ([@B3]). The effectiveness of tigecycline for treating intracranial *A. baumannii* infections is still controversial because of its low CSF penetration level ([@B4]). Thus, the treatment with continuous ventricular irrigation (CVI) and IVT tigecycline may be a fusible way forward.

Herein, we describe the first case of ventriculitis and abscess by MDR *A. baumannii* and clearance following CVI and IVT tigecycline therapy.

Previous case reports and case series, which provided information on the efficacy or safety of tigecycline for ventriculitis or meningitis based on a positive CSF culture (with MDR or XDR *A. baumannii*), were included. Moreover, ventriculitis or meningitis in this study should meet the following criteria: positive CSF culture, fever \>38°C, increased white blood cells (\>10 cells/mm3 with \>50% polymorph), and increased protein and/or decreased glucose levels in the CSF ([@B5]).

The reviewed six articles which met the inclusion criteria, and a total of seven patients with meningitis/ventriculitis due to MDR *A. baumannii*, were included and treated with tigecycline ([@B6]--[@B10], [@B11]). Moreover, we included one case of *A. baumannii* (AB) ventriculitis, with antibiograms for the isolates of AB only susceptible to tigecycline, which were treated with abscess clearance on a ventriculoscope combined with CVI and IVT tigecycline treatment. We followed up the results of the laboratory CSF analusis and the cultures of the specimens to assess the microbiological clearance of the infecting organisms (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}).

###### 

Studies regarding (IV or CVI or IVT) administration of tigecycline in *Acinetobacter baumannii* meningitis/ventriculitis (I).

  **Reference**                                  **([@B10])**                                **([@B11])**                                            **([@B11])**                                            **This study**
  ---------------------------------------------- ------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------
  Age                                            25                                          48                                                      52                                                      55
  Sex                                            male                                        male                                                    male                                                    male
  Underlying disease(s)                          Pilocytic astrocytom hydrocephalus          Vertebral trauma                                        Lumbar disk herniation                                  Intracerebellar hemorrhage, CSF, hydrocephalus
  Foreign body                                   EVD                                         Spinal instrumentation                                  None                                                    EVD
  Days from admission to diagnosis               11                                          10                                                      9                                                       26
  Antimicrobial susceptibilities AB Colimycin;   Susceptible to TGC (MIC = 3.2 μg/mL); MDR   Susceptible to netilmicin, TGC(MIC = 0.38 μg/mL); MDR   Susceptible to netilmicin, TGC(MIC = 0.38 μg/mL); MDR   Susceptible to TGC(MIC = 16 μg/mL); XDR
  Current antimicrobial regimens                 TGC and colimycin and meropenem             TGC, Netilmicin, and meropenem                          TGC, Netilmicin                                         TGC, cefoperazone-sulbactam, amikacin
  IV/CVI/IVT, tigecycline                        IV, 50 mg/q12h                              IV, 50 mg/q12h                                          IV, 50 mg/q12                                           IV, 100 mg/q12h CVI, 10 mg/q12h IVT, 2 mg/q12h
  Co-administered antibiotics                    Colimycin IV, 9MIU/q24                      Netilmicin IV, (400 mg/q24h) Meropenem IV, (2g/q8h)     Netilmicin IV, (400 mg/q24h) Meropenem IV, (2g/q8h)     Cefoperazone-sulbactam IV, (2g/q8h)
  Days to CSF sterilization                      23                                          21                                                      21                                                      12
  Toxicity                                       None                                        None                                                    None                                                    None
  Infection outcome                              Cured                                       Cured                                                   Cured                                                   Cured
  Survival                                       Yes                                         Yes                                                     Yes                                                     Yes

*CSF, cerebrospinal fluid; MIC, minimum inhibitory concentration; EVD, external ventricular drain; MDR, multidrug resistant; XDR, extensively drug-resistant; TGC, tigecycline; q8h, every 8 h; q12h, every 12 h; q24h, every 24 h; IV, intravenous; CVI, continuous ventricular irrigation; IVT, intraventricular*.

###### 

Studies regarding (IV or CVI or IVT) administration of tigecycline in *Acinetobacter baumannii* meningitis/ventriculitis (II).

  **Reference**                      **([@B6])**                                         **([@B7])**                                                           **([@B8])**                                    **([@B9])**
  ---------------------------------- --------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------------------------
  Age                                75                                                  22                                                                    50                                             42
  Sex                                male                                                male                                                                  male                                           male
  Underlying disease(s)              Frontal contusion, subdural hematoma                Giant pituitary adenoma, CSF leak                                     Cranial traumatic brain injury hydrocephalus   Ependymoma 4th ventricle, CSF leak
  Foreign body                       EVD                                                 Fibrin glue, dural substitutes                                        No                                             EVD
  Days from admission to diagnosis   4                                                   18[^a^](#TN1){ref-type="table-fn"}                                    31                                             15
  Antimicrobial susceptibilities     Susceptible to TGC, CST; XDR                        Susceptible to TGC, (MIC = 2 μg/mL); MDR                              Susceptible to TGC; XDR                        Susceptible to TGC(MIC = 0.5 μg/mL) CST(MIC \< 0.5 μg/mL); MDR
  Current antimicrobial regimens     TGC and CST                                         TGC, CST, meropenem and vancomycin                                    Cefoperazone-sulbactam, TGC                    TGC, CST, and amikacin
  IV/CVI/IVT tigecycline             IV,50 mg/q12h                                       IV, 100 mg/q12 h IVT, 2 mg/(q24h-q12h)                                IV, 100 mg/q12 h IVT, (3--4)mg/q12h            IV,50 mg/q12h
  Co-administered antibiotics        CST IV, 2 million IU/q8h IVT, 0.2 million IU/q24h   CST IVT, 120,000/q12h Meropenem IV, 2 g/q8h Vancomycin IV, 1 g/q12h   Cefoperazone-sulbactam IV, 3g/q12h             CST IV, 2 million IU/q6h ITH, 150,000 IU/q24h
  Days to CSF sterilization          7                                                   75                                                                    14                                             20
  Toxicity                           Renal dysfunction (CST)                             Chemical ventriculitis, Myelitis(CST)                                 None                                           None
  Infection outcome                  Cured                                               Cured                                                                 Cured                                          Cured
  Survival                           NR[^b^](#TN2){ref-type="table-fn"}                  Yes                                                                   Yes                                            Yes

CSF, cerebrospinal fluid; MIC, minimum inhibitory concentration; EVD, external ventricular drain; MDR, multidrug resistant; XDR, extensively drug-resistant; TGC, tigecycline; CST, colistin; q6h, every 6 h; q8h, every 8 h; q12h, every 12 h; q24h, every 24 h; IV, intravenous; CVI, continuous ventricular irrigation; IVT, intraventricular; NR, not reported;

*On day 18 after endoscopic transsphenoidal surgery for the removal of a giant pituitary adenoma*.

*Due to progressive worsening of renal function and GCS, the family members of the patient decided to withdraw the support due to anticipated poor neurological outcome despite microbiological cure of ventriculitis. The patient most likely died after discharge*.

Case presentation {#s2}
=================

A 55-year-old male patient, who was admitted to the local medical facility due to the sudden onset of severe headache and loss of consciousness, had a cerebellar hematoma on CT scan. He underwent an emergency placement of an external ventricular drain (EVD) on October 7, 2017. The patient was transferred to our hospital 3 days later because of high fever with Glasgow Coma Scale (GCS) score of 4. Follow-up CT indicated cerebellar hemorrhage in the bilateral and 3rd ventricles (Figure [1](#F1){ref-type="fig"}). CSF from EVD revealed a white blood cell count of 1,280 × 10^6^/L, total protein 4.18 g/L, and glucose 2.26 mmol/L, the simultaneous blood glucose level was 7.5 mmol/L (Table [3](#T3){ref-type="table"}). The sputum culture tested positive for extreme-drug (EXD)-resistant *A. baumannii*, which was sensitive to amikacin only. Thus, pulmonary and intracranial infections were highly suspected, and vancomycin (1 g/day twice daily via IV) and amikacin (0.4 g/day twice daily via IV) were initiated empirically (October 12, 2017). During the follow-up period, the patient\'s fever gradually subsided. The laboratory CSF analysis improved, and the CSF cultures tested negative. However, the bacterial load further increased and the fever recurred.

![Computed tomography imaging before and after admission **(A)**. The patient underwent hematoma removal from the cerebellum and decompression in a local medical facility. Computed tomography after admission to our hospital revealed cerebellar hemorrhage in the bilateral and 3rd ventricles **(B)**. We temporarily placed a bilateral ventricular drainage in the occipital horns after the clearance of abscess on a ventriculoscope on November 3, 2017 **(C)**. We replaced the bilateral ventricular drainage in the frontal horns due to CSF leakage in the occipital horns on November 14, 2017.](fneur-09-00518-g0001){#F1}

###### 

Laboratory tests for CSF in the period of treatment.

  **Date**                      **Oct. 13th**   **Oct. 16th**   **Oct. 19th**   **Oct. 27th**   **Nov. 06th**   **Nov. 15th**   **Nov. 18th**   **Nov. 21th**   **Nov. 24th**   **Nov. 25th**   **Nov. 28th**   **Jan. 17th**   **Normal values**
  ----------------------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- -------------------
  Total cells (× 10^∧^6/L)      4+/HP           25,000          9,280           310             750             30,500          2,560           3,410           180             121             30              4               \< 10
  WBC (× 10^∧^6/L)              1,280           320             1,090           46              75              300             0               2               2               4               0               0               \< 8
  Poly-karyocyte (× 10^∧^6/L)   896             288             981             37              60              270             0               0               0               0               0               0               \< 5
  Protein (g/L)                 4.18            3.93            3.62            2.81            1.42            1.46            0.64            0.32            1.74            3.45            2.69            2.44            0.15--0.45
  Glucose (mmol/L)              2.26            1.37            3.93            5.24            1.51            5.46            2.81            3.27            8.90            5.40            5.46            2.87            2.50--4.40
  Chlorine (mmol/L)             120.6           127.3           116.1           113.3           127.7           124.3           136.9           138.3           118.4           126.5           124             115.8           120.0--130.0

*CSF, cerebrospinal fluid; Oct, October; Nov, November; Jan, January; WBC, white blood cell*.

On October 31, 2017, magnetic resonance imaging revealed hydrocephalus and interstitial edema beside bilateral ventricles. In addition, occipital horn enhancement bilaterally suggested intracranial infection (Figure [2](#F2){ref-type="fig"}). An endoscopic ventriculostomy was done, a large amount of pus was removed from the ventricles (Figure [3](#F3){ref-type="fig"}), and two EVDs were placed for antibiotic therapy (bilateral occipital horn; Figure [1](#F1){ref-type="fig"}). The CSF cultures revealed an XDR strain of *A. baumannii* (November 6, 2017) and a minimum inhibitory tigecycline concentration of 16 μg/mL. On November 8, 2017, the patient was administered tigecycline (100 mg twice daily via IV), cefoperazone sulbactam (2 g every time, thrice daily via IV), and CVI tigecycline (10 mg/500 mL saline twice daily, in from the right occipital horn and out from the left horn). A leakage was observed around the drainage tube 4 days later. This was probably because we had to exchange the in-out tube, due to the frequent obstruction of the drainage tube or to the rather short (\< 3 cm) subcutaneous tunnel of the drainage tube. Although the dressing was changed twice daily and the wound was sutured several times, the leakage persisted. Therefore, on November 14, 2017, we removed the two occipital horn drainage tubes and replaced it with two frontal horn drainage tubes with a bigger size (12\#) and a longer subcutaneous tunneling (10 cm) (Figure [1](#F1){ref-type="fig"}). Perioperative antibiotics were administered and the leakage stopped. Twelve days from the start of the CVI tigecycline, the signs of ventriculitis disappeared, and the *Acinetobacter* CSF load steadily decreased until CSF sterilization. Thus, we adjusted the IVT tigecycline dosage to 50 mg twice daily, whereas CVI tigecycline was adjusted to IVT tigecycline (2 mg twice daily). Tigecycline was diluted in saline up to 4 mL and was slowly injected into the lateral ventricles via EVD. After every injection, the CSF drain was temporarily closed for 2 h to prevent the untimely washout of the drug. The tigecycline treatment was well tolerated by the patient. The ventricular drainage tubes were removed, and the antibiotic therapy was discontinued after 1 week of persistent negative CSF cultures and laboratory CSF analysis (Table [3](#T3){ref-type="table"}). The follow-up MRI (November 27, 2017) was negative for ventriculitis (Figure [2](#F2){ref-type="fig"}). Thus, on November 29, 2017, 14 days after the restart of the CVI tigecycline and 3 days after the IVT tigecycline, the patient was transferred to a rehabilitation unit.

![Brain MRI obtained before **(A)** and after **(B)** abscess clearance combined with tigecycline treatment **(A)**. MRI on October 31, 2017 showed that interstitial cerebral edemas beside the ventricles and bilateral ventricular occipital horn enhancement along with hydrocephalus, which indicated signs of ventriculitis **(B)**. MRI after abscess clearance combined with tigecycline treatment revealed the disappearance of the edemas, ventricular enhancement, and hydrocephalus.](fneur-09-00518-g0002){#F2}

![Abscess clearance on a ventriculoscope. Large amount of cellulose deposition in the ventricles were observed on a ventriculoscope, and the lesion was infected, which needed neurosurgery.](fneur-09-00518-g0003){#F3}

The GCS score of the patient was 10 (E4VM5) after 2 months of follow-up, and the symptoms of intracranial infection were not observed. Repeated CSF cultures were all negative, and no radiological signs of neuro-inflammation were found. The laboratory tests for CSF during follow-up (January 17, 2018) are shown in Table [3](#T3){ref-type="table"}.

Discussion {#s3}
==========

In the present report, we presented a patient with ventricular infection from XDR *A. baumannii* and they were successfully treated using abscess clearance on a ventriculoscope in combination with CVI and IVT tigecycline therapy. To the best of our knowledge, the use of such a therapeutic approach has not been previously reported. Nowadays, the IVT administration of colistin is practiced in life threatening CNS infections for *A. baumannii* meningitis/ventriculitis ([@B12]). Nevertheless, the serious nephrological and neurological side effects, such as chemical ventriculitis, chemical meningitis, and seizures, limit wide application ([@B2], [@B13]).

Tigecycline is a novel class of antibiotics designed to overcome drug resistance ([@B14]). It has been previously reported that tigecycline has an effect against vancomycin-resistant *Enterococci*, methicillin-resistant *Staphylococcus aureus*, penicillin-resistant *Streptococcus pneumoniae*, and numerous species of the MDR gram-negative bacteria ([@B14]). In addition, tigecycline has a favorable toxicity profile, particularly regarding adverse events involving the nervous system ([@B14]). In contrast to these advantages, the BBB penetration rate of tigecycline is only approximately 11% ([@B14]). Therefore, to limit the influence of this shortage, we considered combining IV and CVI with IVT tigecycline that may be a potential treatment alternative for our patient. CVI tigecycline in addition to IV and (or) IVT tigecycline was not used in previous studies, and yet, patients in previous studies were cured ([@B6]--[@B11]). We administered CVI tigecycline because our patients developed a local infection of the lesions in the bilateral ventricles, and a large amount of cellulose deposite was observed in the ventricles using a ventriculoscope. Moreover, we hypothesized that this new treatment, which completely cleared the abscess, is more efficient in controlling infection and reducing postoperative adhesion. Based on our results, this route was well tolerated and had excellent outcomes.

The dosages as well as the length of IV and IVT tigecycline treatment in the reported cases varied significantly. The most commonly used IV dosage ranged from 100 to 200 mg/day, and two doses were administered. However, the IVT dosage had a distribution of 2--8 mg/day. The length of intraventricular therapy also varies between 7 and 75 days in published cases ([@B6], [@B7]). We selected the lowest effective dosage of IV tigecycline (200 mg/day), because our patients also developed pneumonia due to XDR *A. baumannii*. With regard to IVT dosage, we chose 4 mg/day to minimize adverse effects. Twelve days after restarting CVI tigecycline, the CSF cultures tested negative, and to the best of our knowledge, this is the most rapid therapy in decreasing bacterial load without serious complications. As for the reasons why patients became infected with *A. baumannii*, based on our results and previous studies, foreign bodies, like external ventricular drain during neurosurgery and long-term neurosurgical intensive care unit (NICU) hospitalization were responsibile for those infections. We believe that this three-step approach (abscess clearance to CVI to IVT) could be important in managing MDR ventricular infections. Our patient was cured, which is similar to the previously reported cases. However, because this report only involved one patient and the use of this treatment is limited, we cannot predict the accuracy rate of the treatment and its side effects. Therefore, more studies must be conducted to demonstrate the therapeutic effects of this schedule. If confirmed to be safe and effective in the future, besides IVT colistin, this three-step approach, namely, abscess clearance in combination with CVI (bilateral frontal horn, subcutaneous tunnel \>10 cm) and IVT tigecycline, could also be considered as the first-line therapy for patients with MDR intracranial infections.

Conclusions {#s4}
===========

The use of multi-route (CVI and IVT) tigecycline and IVT colistin for MDR/XDR ventriculitis is effective, and those treatment options should be considered as a valuable therapy in managing these life-threatening intraventricular infections. However, more studies must be conducted to demonstrate the therapeutic effects.
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BBB

:   blood--brain barrier

CSF

:   cerebrospinal fluid

CVI

:   continuous ventricular irrigation

EVD

:   external ventricular drain

IV

:   intravenous

IVT

:   intraventricular

MDR

:   multidrug-resistant

XDR

:   extreme drug-resistant.
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